CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Evaluation of Bevacizumab (Anti-VEGF Humanized Monoclonal Antibody) (NSC #704865) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00022659
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:12.996146+00:00
Published At: 2015-05-12T00:00:00+00:00
Record Updated At: 2019-07-24
Results Posted At: 2015-05-12
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Primary Peritoneal Cavity Cancer", "Recurrent Ovarian Epithelial Cancer", "Stage IV Ovarian Epithelial Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-07-24"
protocolSection.identificationModule.nctId: "NCT00022659"
protocolSection.identificationModule.officialTitle: "A Phase II Evaluation of Bevacizumab (Anti-VEGF Humanized Monoclonal Antibody) (NSC #704865) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2015-05-12"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.